Osteoporosis: Now and the future

The Lancet

Volumn 377, Issue 9773, 2011, Pages 1276-1287

  Rachner, Tilman D ^a   Khosla, Sundeep ^b   Hofbauer, Lorenz C ^a,c  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b MAYO CLINIC   (United States)

^c CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; AMG 785; ANABOLIC AGENT; ANTIBODY; AROMATASE INHIBITOR; BHQ 880; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CATHEPSIN K INHIBITOR; CHLORIDE CHANNEL BLOCKING AGENT; DENOSUMAB; DICKKOPF 1 PROTEIN; IBANDRONIC ACID; MK 5442; NS 3736; ODANACATIB; ONO 5334; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; SARACATINIB; SCLEROSTIN; SCLEROSTIN ANTIBODY; STRONTIUM RANELATE; UNCLASSIFIED DRUG; VITAMIN D; ZOLEDRONIC ACID;

ABDOMINAL DISCOMFORT; ACUTE PHASE RESPONSE; ALCOHOL CONSUMPTION; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE DENSITY; BONE METASTASIS; BONE REMODELING; BREAST CANCER; CARDIOVASCULAR DISEASE; CATARACT; CELL DIFFERENTIATION; CELLULITIS; CORTICOSTEROID INDUCED OSTEOPOROSIS; DIARRHEA; DOSE RESPONSE; DRESS SYNDROME; DRUG EFFICACY; DRUG MECHANISM; DRUG WITHDRAWAL; ECZEMA; ERYSIPELAS; ESOPHAGUS DISEASE; ESOPHAGUS IRRITATION; FEMUR SUBTROCHANTERIC FRACTURE; GASTROINTESTINAL SYMPTOM; HIP FRACTURE; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; INFECTION; JAW OSTEONECROSIS; LIFESTYLE MODIFICATION; MYELOMA; NAUSEA; NEOPLASM; NEPHROTOXICITY; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOCYTE; OSTEOLYSIS; OSTEOPOROSIS; OSTEOSARCOMA; PAGET BONE DISEASE; PATHOGENESIS; PHYSICAL ACTIVITY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; SCLERODERMA; SIDE EFFECT; SINGLE DRUG DOSE; SMOKING CESSATION; THROMBOEMBOLISM; VERTEBRA FRACTURE; VITAMIN DEFICIENCY;

EID: 79953751008     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)62349-5     Document Type: Review

References (92)

1. NIH Consensus Development Panel on Osteoporosis Prevention Diagnosis, and Therapy Osteoporosis prevention, diagnosis, and therapy JAMA 285 2001 785 795
2. LJ Melton 3rd, EA Chrischilles, C Cooper, AW Lane, BL Riggs Perspective: how many women have osteoporosis? J Bone Miner Res 7 1992 1005 1010
3. R Burge, B Dawson-Hughes, DH Solomon, JB Wong, A King, A Tosteson Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025 J Bone Miner Res 22 2007 465 475 (Pubitemid 46797130)
4. NF Ray, JK Chan, M Thamer, LJ Melton 3rd Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation J Bone Miner Res 12 1997 24 35 (Pubitemid 27053608)
5. JR Center, TV Nguyen, D Schneider, PN Sambrook, JA Eisman Mortality after all major types of osteoporotic fracture in men and women: an observational study Lancet 353 1999 878 882 (Pubitemid 29126875)
6. A Unnanuntana, BP Gladnick, E Donnelly, JM Lane The assessment of fracture risk J Bone Joint Surg Am 92 2010 743 753
7. P Vestergaard, L Rejnmark, L Mosekilde Osteoporosis is markedly underdiagnosed: a nationwide study from Denmark Osteoporos Int 16 2005 134 141 (Pubitemid 40193199)
8. SF Hodgson, NB Watts, JP Bilezikian for the AACE Osteoporosis Task Force American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003 Endocr Pract 9 2003 544 564
9. J Compston, A Cooper, C Cooper on behalf of the National Osteoporosis Guideline Group (NOGG) Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK Maturitas 62 2009 105 108
10. JP Brown, RG Josse Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada CMAJ 167 2002 S1 34
11. JA Kanis Diagnosis of osteoporosis and assessment of fracture risk Lancet 359 2002 1929 1936 (Pubitemid 34615775)
12. SR Cummings, D Bates, DM Black Clinical use of bone densitometry: scientific review JAMA 288 2002 1889 1897 (Pubitemid 35168145)
13. RM Zebaze, A Ghasem-Zadeh, A Bohte Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study Lancet 375 2010 1729 1736
14. MF Holick Vitamin D deficiency N Engl J Med 357 2007 266 281
15. MJ Bolland, A Avenell, JA Baron Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis BMJ 341 2010 c3691
16. J Hsia, G Heiss, H Ren for the Women's Health Initiative Investigators Women's Health Initiative Investigators. Calcium/vitamin D supplementation and cardiovascular events Circulation 115 2007 846 854 (Pubitemid 46294725)
17. DM Black, SR Cummings, DB Karpf for the Fracture Intervention Trial Research Group Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures Lancet 348 1996 1535 1541 (Pubitemid 26411651)
18. SR Cummings, DM Black, DE Thompson Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial JAMA 280 1998 2077 2082 (Pubitemid 29014065)
19. MR McClung, P Geusens, PD Miller for the Hip Intervention Program Study Group Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group N Engl J Med 344 2001 333 340 (Pubitemid 32107641)
20. ST Harris, NB Watts, HK Genant for the Vertebral Efficacy With Risedronate Therapy (VERT) Study Group Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group JAMA 282 1999 1344 1352 (Pubitemid 29483192)
21. CH Chesnut III, A Skag, C Christiansen Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis J Bone Miner Res 19 2004 1241 1249 (Pubitemid 41094364)
22. DM Black, PD Delmas, R Eastell Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis N Engl J Med 356 2007 1809 1822 (Pubitemid 46698462)
23. PD Delmas, KE Ensrud, JD Adachi for the HORIZON Pivotal Fracture Trial Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial J Clin Endocrinol Metab 87 2002 3609 3617 (Pubitemid 34879503)
24. JY Reginster, E Seeman, MC De Vernejoul Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study J Clin Endocrinol Metab 90 2005 2816 2822 (Pubitemid 40686329)
25. PJ Meunier, C Roux, E Seeman The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis N Engl J Med 350 2004 459 468 (Pubitemid 38133766)
26. RM Neer, CD Arnaud, JR Zanchetta Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis N Engl J Med 344 2001 1434 1441 (Pubitemid 32402100)
27. SL Greenspan, HG Bone, MP Ettinger for the Treatment of Osteoporosis with Parathyroid Hormone Study Group Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial Ann Intern Med 146 2007 326 339 (Pubitemid 351650593)
28. PE Daddona, JA Matriano, J Mandema, YF Maa Parathyroid hormone (1-34)-coated microneedle patch system: clinical pharmacokinetics and pharmacodynamics for treatment of osteoporosis Pharm Res 2010 10.1007/s11095-010-0192-9 published online June 22.
29. ES Siris, PL Selby, KG Saag, F Borgstrom, RM Herings, SL Silverman Impact of osteoporosis treatment adherence on fracture rates in North America and Europe Am J Med 122 suppl 2 2009 S3 13
30. P Sambrook, C Cooper Osteoporosis Lancet 367 2006 2010 2018 (Pubitemid 43867702)
31. YY Kong, H Yoshida, I Sarosi OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis Nature 397 1999 315 323
32. WS Simonet, DL Lacey, CR Dunstan Osteoprotegerin: a novel secreted protein involved in the regulation of bone density Cell 89 1997 309 319 (Pubitemid 27199902)
33. G Eghbali-Fatourechi, S Khosla, A Sanyal, WJ Boyle, DL Lacey, BL Riggs Role of RANK ligand in mediating increased bone resorption in early postmenopausal women J Clin Invest 111 2003 1221 1230 (Pubitemid 36519939)
34. LC Hofbauer, F Gori, BL Riggs Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis Endocrinology 140 1999 4382 4389 (Pubitemid 30666099)
35. LC Hofbauer, S Khosla, CR Dunstan, DL Lacey, TC Spelsberg, BL Riggs Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells Endocrinology 140 1999 4367 4370 (Pubitemid 30647136)
36. LC Hofbauer, DL Lacey, CR Dunstan, TC Spelsberg, BL Riggs, S Khosla Interleukin-1β and tumor necrosis factor-α, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells Bone 25 1999 255 259 (Pubitemid 29406050)
37. YY Kong, U Feige, I Sarosi Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand Nature 402 1999 304 309
38. YT Teng, H Nguyen, X Gao Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection J Clin Invest 106 2000 R59 R67
39. RN Pearse, EM Sordillo, S Yaccoby Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression Proc Natl Acad Sci USA 98 2001 11581 11586 (Pubitemid 32928771)
40. S Morony, C Capparelli, I Sarosi, DL Lacey, CR Dunstan, PJ Kostenuik Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis Cancer Res 61 2001 4432 4436 (Pubitemid 32685771)
41. P Soriano, C Montgomery, R Geske, A Bradley Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice Cell 64 1991 693 702 (Pubitemid 121001157)
42. BF Boyce, T Yoneda, C Lowe, P Soriano, GR Mundy Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice J Clin Invest 90 1992 1622 1627
43. M Marzia, NA Sims, S Voit Decreased c-Src expression enhances osteoblast differentiation and bone formation J Cell Biol 151 2000 311 320
44. BD Gelb, GP Shi, HA Chapman, RJ Desnick Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency Science 273 1996 1236 1238
45. P Saftig, E Hunziker, V Everts Functions of cathepsin K in bone resorption. Lessons from cathepsin K deficient mice Adv Exp Med Biol 477 2000 293 303 (Pubitemid 32174016)
46. EM Brown The calcium-sensing receptor: physiology, pathophysiology and CaR-based therapeutics Subcell Biochem 45 2007 139 167
47. SJ Steddon, J Cunningham Calcimimetics and calcilytics - fooling the calcium receptor Lancet 365 2005 2237 2239 (Pubitemid 40853917)
48. O Fromigue, E Hay, A Barbara Calcium sensing receptor-dependent and receptor-independent activation of osteoblast replication and survival by strontium ranelate J Cell Mol Med 13 2009 2189 2199
49. R Baron, G Rawadi Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton Endocrinology 148 2007 2635 2643 (Pubitemid 46984775)
50. E Canalis, A Giustina, JP Bilezikian Mechanisms of anabolic therapies for osteoporosis N Engl J Med 357 2007 905 916
51. KE Poole, RL van Bezooijen, N Loveridge Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation FASEB J 19 2005 1842 1844 (Pubitemid 41598769)
52. PJ Bekker, D Holloway, A Nakanishi, M Arrighi, PT Leese, CR Dunstan The effect of a single dose of osteoprotegerin in postmenopausal women J Bone Miner Res 16 2001 348 360 (Pubitemid 32105416)
53. JG Emery, P McDonnell, MB Burke Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL J Biol Chem 273 1998 14363 14367 (Pubitemid 28319153)
54. PJ Bekker, DL Holloway, AS Rasmussen A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women J Bone Miner Res 19 2004 1059 1066 (Pubitemid 41110556)
55. MR McClung, EM Lewiecki, SB Cohen Denosumab in postmenopausal women with low bone mineral density N Engl J Med 354 2006 821 831 (Pubitemid 43290920)
56. EM Lewiecki, PD Miller, MR McClung Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD J Bone Miner Res 22 2007 1832 1841 (Pubitemid 351229299)
57. PD Miller, MA Bolognese, EM Lewiecki for the AMG 162 Bone Loss Study Group Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial Bone 43 2008 222 229
58. I Reid, P Miller, J Brown on behalf of the Denosumab Phase 3 Bone Histology Study Group Effects of denosumab on bone histomorphometry: The FREEDOM and STAND studies J Bone Miner Res 25 2010 2256 2265
59. SR Cummings, J San Martin, MR McClung for the FREEDOM Trial Denosumab for prevention of fractures in postmenopausal women with osteoporosis N Engl J Med 361 2009 756 765
60. JP Brown, RL Prince, C Deal Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial J Bone Miner Res 24 2009 153 161
61. AT Stopeck, A Lipton, JJ Body Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study J Clin Oncol 28 2010 5132 5139
62. HG Bone, MA Bolognese, CK Yuen Effects of denosumab on bone mineral density and bone turnover in postmenopausal women Clin Endocrinol Metab 93 2008 2149 2157 (Pubitemid 351831529)
63. GK Ellis, HG Bone, R Chlebowski Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer J Clin Oncol 26 2008 4875 4882
64. MR Smith, B Egerdie, N Hernandez Toriz for the Denosumab HALT Prostate Cancer Study Group Denosumab in men receiving androgen-deprivation therapy for prostate cancer N Engl J Med 361 2009 745 755
65. M Stolina, PJ Kostenuik, WC Dougall, LA Fitzpatrick, DJ Zack RANKL inhibition: from mice to men (and women) Adv Exp Med Biol 602 2007 143 150
66. S Khosla, D Burr, J Cauley Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research J Bone Miner Res 22 2007 1479 1491 (Pubitemid 351229318)
67. JY Gauthier, N Chauret, W Cromlish The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K Bioorg Med Chem Lett 18 2008 923 928 (Pubitemid 351179363)
68. A Peroni, A Zini, V Braga, C Colato, S Adami, G Girolomoni Drug-induced morphea: report of a case induced by balicatib and review of the literature J Am Acad Dermatol 59 2008 125 129
69. SA Stoch, S Zajic, J Stone Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies Clin Pharmacol Ther 86 2009 175 182
70. HG Bone, MR McClung, C Roux Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density J Bone Miner Res 25 2010 937 947
71. RS Weinstein, PK Roberson, SC Manolagas Giant osteoclast formation and long-term oral bisphosphonate therapy N Engl J Med 360 2009 53 62
72. RA Hannon, G Clack, M Rimmer Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial J Bone Miner Res 25 2010 463 471
73. DB Henriksen, P Alexandersen, NH Bjarnason Role of gastrointestinal hormones in postprandial reduction of bone resorption J Bone Miner Res 18 2003 2180 2189 (Pubitemid 37463311)
74. DB Henriksen, P Alexandersen, B Hartmann Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD Bone 45 2009 833 842
75. S Schaller, K Henriksen, C Sveigaard The chloride channel inhibitor NS3736 [corrected] prevents bone resorption in ovariectomized rats without changing bone formation J Bone Miner Res 19 2004 1144 1153 (Pubitemid 41110567)
76. M Gowen, GB Stroup, RA Dodds Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats J Clin Invest 105 2000 1595 1604 (Pubitemid 30390310)
77. G Balan, J Bauman, S Bhattacharya The discovery of novel calcium sensing receptor negative allosteric modulators Bioorg Med Chem Lett 19 2009 3328 3332
78. S Kumar, CJ Matheny, SJ Hoffman An orally active calcium-sensing receptor antagonist that transiently increases plasma concentrations of PTH and stimulates bone formation Bone 46 2010 534 542
79. JJ Westendorf, RA Kahler, TM Schroeder Wnt signaling in osteoblasts and bone diseases Gene 341 2004 19 39 (Pubitemid 39335880)
80. LH Hoeppner, FJ Secreto, JJ Westendorf Wnt signaling as a therapeutic target for bone diseases Expert Opin Ther Targets 13 2009 485 496
81. W Balemans, M Ebeling, N Patel Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST) Hum Mol Genet 10 2001 537 543 (Pubitemid 32184286)
82. GG Loots, M Kneissel, H Keller Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease Genome Res 15 2005 928 935 (Pubitemid 40994212)
83. X Li, MS Ominsky, KS Warmington Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis J Bone Miner Res 24 2009 578 588
84. MS Ominsky, F Vlasseros, J Jolette Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength J Bone Miner Res 25 2010 948 959
85. D Padhi, B Stouch, G Jang Anti-sclerostin antibody increases markers of bone formation in healthy postmenopausal women J Bone Miner Res 22 suppl 1 2007 S37
86. D Diarra, M Stolina, K Polzer Dickkopf-1 is a master regulator of joint remodeling Nat Med 13 2007 156 163
87. DJ Heath, AD Chantry, CH Buckle Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma J Bone Miner Res 24 2009 425 436
88. M Fulciniti, P Tassone, T Hideshima Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma Blood 114 2009 371 379
89. RH Giles, JH van Es, H Clevers Caught up in a Wnt storm: Wnt signaling in cancer Biochim Biophys Acta 1653 2003 1 24 (Pubitemid 36627817)
90. M Kansara, M Tsang, L Kodjabachian Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice J Clin Invest 119 2009 837 851
91. ME Brunkow, JC Gardner, J Van Ness Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein Am J Hum Genet 68 2001 577 589 (Pubitemid 32202753)
92. E Canalis Update in new anabolic therapies for osteoporosis J Clin Endocrinol Metab 95 2010 1496 1504